Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE versus FLOVENT DISKUS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE versus FLOVENT DISKUS 250.
DEXAMETHASONE vs FLOVENT DISKUS 250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
None Documented
None Documented
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Category D/X
Category C
Corticosteroid
Corticosteroid